1. Academic Validation
  2. BTK inhibition suppresses neuroinflammation and neurodegeneration in amyotrophic lateral sclerosis

BTK inhibition suppresses neuroinflammation and neurodegeneration in amyotrophic lateral sclerosis

  • Brain. 2026 Feb 19:awag070. doi: 10.1093/brain/awag070.
Qing Liu 1 2 Xinzhe Zhang 3 Lijing Wang 1 Haodong Chen 1 Gaojie Wang 1 Ye Sun 1 Baodong He 1 Jiao Gao 1 Wenying Qiu 4 Chao Ma 4 Miao Sun 2 3 Liying Cui 1 2 Xue Zhang 2 3
Affiliations

Affiliations

  • 1 Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Science (CAMS) & Peking Union Medical College (PUMC), 100050, China.
  • 2 State Key Laboratory of Complex, Severe, and Rare Diseases, PUMCH, 102602, China.
  • 3 Mckusick-Zhang Center for Genetic Medicine, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, CAMS & PUMC, 100050, China.
  • 4 Institute of Basic Medical Sciences, Neuroscience Center, National Human Brain Bank for Development and Function; Department of Human Anatomy, Histology and Embryology, CAMS & PUMC, 100050, China.
Abstract

Amyotrophic lateral sclerosis(ALS) is a devastating neurodegenerative disorder with limited therapeutic interventions. Neuroinflammation represents a central pathogenic mechanism in ALS, yet the upstream molecular regulators that integrate multiple inflammatory cascades remain poorly understood. Here, we investigated whether Bruton's tyrosine kinase (Btk), which integrates DNA-sensing and Toll-like Receptor signals upstream of the cGAS-STING-NF-κB cascade, serves as a key regulatory node in ALS pathogenesis. Public RNA-seq datasets of motor neurons and post-mortem tissues from ALS patients were utilized to identify Btk expression patterns. SOD1-mutant human induced pluripotent stem cells (hiPSC) were differentiated into motor neurons (hiPSC-MNs) and microglia (hiPSC-MGs). NF-κB dysregulation was profiled by scRNA-seq (hiPSC-MGs) and bulk RNA-seq (hiPSC-MNs). DNA damage (γH2AX), inflammatory signalling (western blot/ELISA) and phagocytosis (pH-rodo uptake) were quantified, and MG-conditioned medium was tested for MN toxicity. Monocultures and MN-MG co-cultures received zanubrutinib (3 µM, 12 h). SOD1-G93A mice were administered zanubrutinib (30 mg/kg, daily) from 2.5 months; motor performance, survival, spinal histology and PI3K-AKT-mTOR activity were assessed after 2 months of treatment. ALS spinal cord and cortex tissues of patients, as well as SOD1-mutant hiPSC-MGs and hiPSC-MNs, demonstrated elevated Btk phosphorylation with increased p-STING, p-TBK1, and nuclear NF-κB accumulation. ALS hiPSC-MGs exhibited inflammatory activation, NLRP3 induction, and impaired phagocytosis, while ALS hiPSC-MNs showed DNA damage and caspase-3-mediated Apoptosis. Conditioned medium from inflammatory microglia amplified neuronal STING-NF-κB activity and Apoptosis, demonstrating non-cell-autonomous toxicity. The STING inhibitor H-151 reduced neuronal p-STING/p-TBK1/NF-κB and Apoptosis, confirming pathway causality. Pharmacological Btk inhibition reduced DNA damage in ALS hiPSC-MNs by 61.4% (p<0.05), restored phagocytosis in ALS hiPSC-MGs to 87.2% of control levels (p<0.01), and prevented neuronal Apoptosis induced by microglial conditioned medium. In SOD1-G93A mice, Btk blockade extended median survival from 158 to 173 days (p<0.01, log-rank test), improved motor function, and attenuated neuroinflammation while moderately rebalancing PI3K-AKT-mTOR signaling without impairing autophagy-lysosome dynamics. We identify Btk as a critical upstream regulator of the dysregulated cGAS-STING-NF-κB signalling axis characteristic of ALS pathogenesis. Btk orchestrates both cell-autonomous dysfunction in motor neurons and non-cell-autonomous toxicity through microglial activation, representing a convergent regulatory node that integrates multiple pathogenic pathways. These mechanistic insights provide a molecular framework for understanding ALS neuroinflammation and establish a rational basis for BTK-targeted therapeutic intervention in neurodegeneration.

Keywords

BTK inhibitor; STING-NF-κB pathway; amyotrophic lateral sclerosis; neuroinflammation.

Figures
Products